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A 6-Month Open-Label Extension Study
of Vortioxetine in Pediatric Patients
with Depressive or Anxiety Disorders
Robert L. Findling, MD, MBA,1 Adelaide S. Robb, MD,2 Melissa P. DelBello, MD, MS,3 Michael Huss, MD,4
Nora K. McNamara, MD,5 Elias H. Sarkis, MD,6 Russell E. Scheffer, MD,7 Lis H. Poulsen, MD, PhD,8
Grace Chen, PhD,9 Ole M. Lemming, MSc,10 and Philippe Auby, MD8

Abstract

Objectives: In this 6-month open-label extension (OLE) of NCT01491035 (a 14-day, open-label, pharmacokinetic/safety
lead-in study), the long-term safety and tolerability of vortioxetine (5–20 mg/day) were investigated in children and adolescents with a DSM-IV-TR diagnosis of depressive or anxiety disorder in the United States or Germany. The study also was
designed to provide data to inform dose selection and titration in future pediatric studies with vortioxetine.
Methods: Safety evaluations included spontaneously reported adverse events (AEs), the Columbia Suicide Severity Rating
Scale (C-SSRS), and the Pediatric Adverse Events Rating Scale (PAERS; clinician administered). Clinical effectiveness was
determined by Clinical Global Impressions. Comorbid attention-deficit/hyperactivity disorder was permitted, including
concomitant use of stimulant medication (US sites only).
Results: Of the 47 patients who completed the lead-in period, 41 continued into the OLE. Most patients (n = 39 [95%]) continued
their previous dose regimen. Twenty-one patients (51%) withdrew during the OLE; the most common primary reasons were
administrative [n = 8], AEs [n = 4], and lack of efficacy [n = 3]. Thirty-five patients (85%) had ‡1 AE, 86% of which were mild
or moderate in severity. Five patients (12%) reported a severe AE, none of which was considered related to study medication.
The most common AEs (‡10%) were headache (27%), nausea (20%), dysmenorrhea (females; 19%), and vomiting (15%), with
no relationship between AE intensity and age or dose. Five patients reported instances of suicidal ideation during the OLE, one of
whom also reported this during the lead-in period. Two patients had nonsuicidal self-injurious behavior; one had a nonfatal
suicide attempt. Throughout the study, there was a decrease over time in the incidence and intensity of AEs collected using the
PAERS. Effectiveness assessment indicated a trend toward improvement based on numeric results.
Conclusion: This OLE confirms the findings from the lead-in study, which concluded that a dosing strategy of 5–20 mg/day is
safe, well tolerated, and suitable for future clinical studies of vortioxetine in pediatric patients.
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Introduction

D

epression in children and adolescents is a disabling condition that is associated with long-term mental and physical
health problems (Keenan-Miller et al. 2007; Zisook et al. 2007;
Williams et al. 2009; Merikangas et al. 2010; Rottenberg et al.
2014). The National Comorbidity Survey–Adolescent Supplement
(NCS-A) demonstrated that the lifetime and 12-month prevalence
of major depressive disorder (MDD) was 11.0% and 7.5%, respectively, among adolescents aged 13–18 years (Avenevoli et al.
2015). The prevalence for children appears lower (*3%), but has
not been widely studied (Costello et al. 2006; Merikangas et al.
2009, 2010; Williams et al. 2009).
Adolescents with major depression were found to have a fourfold risk of 12-month comorbidity with an anxiety disorder, behavior disorder, substance abuse disorder, or attention-deficit/
hyperactivity disorder (ADHD) compared with adolescents without
depression (Avenevoli et al. 2015). The NCS-A also showed a
correlation between MDD and severe role impairment among adolescents (63% of the study population), with an average of 10 days
‘‘out of role’’ (i.e., unable to function) in the preceding 12 months
(Avenevoli et al. 2015). Relative to MDD onset in adulthood, its
onset in childhood and adolescence is associated with significantly
more severe and recurrent forms of MDD, substantial functional
impairment, and greater illness burden (Keenan-Miller et al. 2007;
Zisook et al. 2007; Williams et al. 2009).
Depression is also strongly associated with suicide and suicidality (Wolitzky-Taylor et al. 2010; Hawton et al. 2013; Holma et al.
2014), and suicide is the third leading cause of death among 10–24year-olds (Centers for Disease Control and Prevention 2015b).
According to the Youth Risk Behavior Surveillance System (Kann
et al. 2016) in a national survey of students in grades 9–12, 17.7%
of them had seriously considered attempting suicide, 14.6% had
made a plan for attempting suicide, and 8.6% had attempted suicide
at least once during the 12 months preceding the survey.
Only two antidepressants (both selective serotonin reuptake inhibitors) are approved for treatment of depression in the pediatric
population: fluoxetine is approved for children and adolescents
(ages ‡8 years) with MDD in the United States (US) and the European Union and escitalopram is approved for adolescents (ages
12–17 years) with MDD in the US.
Vortioxetine is a multimodal-acting antidepressant that acts as
a 5-HT3, 5-HT7, and 5-HT1D receptor antagonist, as well as a 5HT1B receptor partial agonist, 5-HT1A receptor agonist, and inhibitor of the 5-HT transporter in vitro (Bang-Andersen et al.
2011; Mork et al. 2012; Westrich et al. 2012). The efficacy,
safety, and tolerability of vortioxetine have been demonstrated
in numerous trials of adults with MDD (Baldwin et al. 2016;
Thase et al. 2016). Vortioxetine also has been investigated in a
series of single- and multiple-dose pharmacokinetic studies performed to evaluate the effect of age, sex, race, renal impairment,
or hepatic impairment on the pharmacokinetics of vortioxetine.
The studies in patients with hepatic impairment showed no clinically meaningful differences in vortioxetine exposure or the need
for dose adjustments for the intrinsic factors investigated (Chen
et al. 2016).
In response to regulatory requests, the first international pediatric pharmacokinetic/safety study with vortioxetine was

conducted to determine if the dose range approved for adult
patients (5–20 mg/day) is appropriate for pediatric efficacy
and safety studies (ClinicalTrials.gov identifier: NCT01491035;
EudraCT number: 2010-020170-42) (Findling et al. 2017). The
objectives of the lead-in study—a prospective, multinational,
multisite, 14-day, open-label, multiple-dose pharmacokinetic/
safety trial of vortioxetine, 5–20 mg/day, in pediatric patients—
were to assess the pharmacokinetics, safety, and tolerability of
vortioxetine across the dose range, providing data for evidencebased dosing strategies for future pediatric studies.
Forty-eight patients were enrolled: 24 adolescents grouped into
4 cohorts (6 per cohort) and 24 children grouped into 4 cohorts (6
per cohort). Each cohort was assigned to receive vortioxetine, 5, 10,
15, or 20 mg, once daily for 14 days, with uptitration every 2 days
for those assigned to higher dosages. Results of the 14-day lead-in
period have been published and suggest that the exposure, safety,
and tolerability of vortioxetine are similar to those in adults when
an uptitration scheme is used to achieve higher doses (Findling
et al. 2017).
In the present study, a 6-month open-label extension (OLE) of
NCT01491035, the long-term safety and effectiveness of vortioxetine (5–20 mg/day) were investigated in children and adolescents
with a diagnosis of a depressive or anxiety disorder. This OLE was
designed to provide preliminary long-term safety data on the use of
vortioxetine in children and adolescents and to provide further information regarding the dosages and uptitration scheme to be used
in future pediatric studies with vortioxetine.
Methods
This study was designed and performed in accordance with the
principles of the Declaration of Helsinki and conducted by seven
principal investigators, each located at one study site. Six study
sites were in the US and one was in Germany. Each site started
patient enrollment only after approval had been granted by the
appropriate ethics committee or institutional review board. Each
patient provided assent to participate (written or verbal) and their
parent(s) or legal representative(s) provided written informed
consent before initiation in the study. Informed consent and assent
were obtained separately for each study period. Patients were informed that they were free to withdraw from the study at any time,
for any reason, without prejudice.
Study population
Patients who completed the lead-in study were, if judged advisable by the investigator, offered the opportunity to continue in
this optional 6-month OLE with flexible-dose design.
Detailed inclusion and exclusion criteria for participation in the
lead-in study were described previously (Findling et al. 2017).
Briefly, pediatric outpatients aged 7–17 years (inclusive) were eligible at screening if they had a Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, Text Revision (DSM-IVTR), diagnosis of a depressive or anxiety disorder that (as judged
by the investigator) warranted antidepressant therapy. Patients with
comorbid ADHD were allowed to participate, and concomitant
stable treatment with a stimulant was permitted at sites in the US,
but not in Germany.
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Exclusion criteria were as follows: Axis I diagnosis of bipolar
disorder, posttraumatic stress disorder, autism, pervasive developmental disorder, obsessive-compulsive disorder, schizophrenia,
or schizoaffective disorder; significant risk of suicide; inability to
maintain stable stimulant treatment (in the US) or taking a concomitant stimulant (in Germany); and any past or present medical
condition or medication that could interfere with safety, tolerability, or effectiveness assessments or could interfere with study
conduct or interpretation. Because of the limited and strictly exploratory evaluation of treatment effect in this study, there were no
restrictions with respect to psychotherapy before or during the leadin period or during the extension period.
Study design
Pharmacological interventions for depressive and anxiety disorders in children and adolescents are not expected to provide any
benefit if given only for a short period (e.g., 2 weeks). Therefore, if
vortioxetine treatment in the 14-day lead-in study was considered
by the investigator and family to be potentially beneficial for the
patient, participants who completed the lead-in period could continue treatment in the 6-month OLE.
Initially, in the OLE, patients continued on their dosage from the
latter part of the lead-in period. However, during subsequent visits
to the investigative site, the dosage could be uptitrated or downtitrated within the range of 5–20 mg/day based on the investigator’s
clinical judgment. During the lead-in study, an external expert
advisory group evaluated the safety, tolerability, and preliminary
pharmacokinetics before enrollment of new cohorts to allow the
possibility of adjusting dose levels. Dose adjustments in the OLE
were required to be within the range studied in the lead-in period
(e.g., there was no titration to 20 mg until that cohort began).
Screening and baseline procedures for the OLE were performed
on day 0 (visit 12), followed by a 24-week treatment period and a
safety follow-up visit 14 days after the last dose of vortioxetine.
After day 0, patients returned to the study site for safety and effectiveness assessments every 4 weeks until the end of the 24-week
treatment period.
Safety and tolerability assessments
Safety and tolerability assessments included documenting
treatment-emergent adverse events (TEAEs), conducting physical
examinations, performing clinical laboratory tests, and obtaining
vital signs, weight, and electrocardiograms (ECGs). Data on
TEAEs, vital signs, and weight were collected at each return visit
(every 4 weeks: days 28, 56, 84, 112, 140, and 168 of the OLE) until
the end of the 24-week treatment period. In addition, a safety
follow-up visit was conducted 2 weeks after the last dose of vortioxetine to collect information on new adverse events (AEs) and to
follow-up on the outcome of AEs ongoing at the end of the treatment period. Specimens for clinical laboratory testing were collected on day 84 (visit 3) and day 168 (visit 18). ECGs and physical
examination were performed on day 168.
Tolerability also was assessed using the Pediatric Adverse Event
Rating Scale (PAERS) (March 2007; Shapiro et al. 2009), which
was to be completed at each return visit, after the open nonleading
question for TEAEs was asked and answered. The PAERS is a
validated instrument for assessing the frequency and severity of
solicited events frequently observed in pediatric patient populations under treatment with psychotropic medication.
Suicidality was evaluated using the Columbia Suicide Severity
Rating Scale (C-SSRS) (Posner et al. 2007, 2011), a semistructured
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interview for systematic assessment of the presence and severity of
suicidal ideation and suicidal behavior in clinical trials. Patient’s
history with suicidality also was assessed using the C-SSRS, which
was administered following the PAERS at each return visit. Both
the PAERS and C-SSRS were administered by psychiatrists or
clinicians who had completed a rater training and certification
program. Each individual patient was to be rated by the same
certified rater throughout the OLE.
Effectiveness assessments
Effectiveness was assessed with the Clinical Global
Impressions–Severity of Illness (CGI-S) and Clinical Global
Impressions–Improvement (CGI-I) scales. CGI-S and CGI-I scores
for the OLE were collected every 4 weeks at each return visit (days
28, 56, 84, 112, 140, and 168 of the OLE) until the end of the 24week extension treatment period. As with the safety and tolerability
assessments, each patient’s scoring on the CGI scales was done by a
trained and certified rater who remained constant throughout the
OLE.
Statistical methods
Safety and effectiveness assessments were based on the OLE
data set, which included all patients who took at least one dose of
vortioxetine in the lead-in period and continued into the optional
6-month extension period. Because investigators had the option to
adjust the dose during the OLE, the extension-period dose was
defined by the assigned cohort from the lead-in period and by modal
dose (defined as the daily dose taken daily for most of both study
periods). For safety and effectiveness, summary statistics are presented for continuous variables and counts and percentages are
presented for categorical variables.
Safety and tolerability data are summarized by cohort and visit,
using descriptive techniques. For patients who continued in the
extension period, safety results are presented for the entire study
(both periods), except for TEAEs and PAERS, which are provided
only for the extension period.
Because the study did not include a placebo control, the effectiveness assessments (CGI-S and CGI-I) were strictly exploratory;
the findings are summarized by cohort and visit for the entire study
(i.e., from beginning of the lead-in period to end of OLE), using
descriptive techniques. Effectiveness results are based on observed
cases (OC) for the extension set, defined as all patients who received at least one dose of study medication and continued into the
extension period.
Results
Of the 47 patients who completed the lead-in period, 41 (22
adolescents and 19 children) entered the OLE (Table 1). Reasons
for not continuing into the OLE (one adolescent and five children)
were lack of efficacy (n = 2), magnitude of commitment (n = 1),
going away to college (n = 1), and missing parental consent to
continue (n = 1); one patient did not specify a reason. Of the 17
patients with concurrent ADHD, 7 (2 adolescents and 5 children)
were treated for ADHD during the lead-in period as well as the
OLE; all 7 patients received stimulants. Medications that were
discontinued before administration of the first dose of vortioxetine
in the lead-in period are listed in Supplementary Table S1 (Supplementary Data are available online at www.liebertpub.com/cap).
Comorbid psychiatric conditions are listed in Supplementary
Table S2.

24 (59)
8 (20)
9 (22)
5 (83)
0
1 (17)
AC, adolescent cohort; CC, child cohort; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.

3 (50)
1 (17)
2 (33)
2 (40)
2 (40)
1 (20)
3 (75)
0
1 (25)

3 (60)
1 (20)
1 (20)

1 (20)
3 (60)
1 (20)

2 (50)
1 (25)
1 (25)

5 (83)
0
1 (17)

25 (61)
13 (32)
3 (7)
4 (67)
2 (33)
0
4 (67)
2 (33)
0
3 (60)
2 (40)
0
2 (50)
1 (25)
1 (25)

2 (40)
3 (60)
0

3 (60)
2 (40)
0

3 (75)
0
1 (25)

4 (67)
1 (17)
1 (17)

20 (49)
21 (51)
2 (33)
4 (67)
3 (50)
3 (50)
3 (60)
2 (40)
2 (50)
2 (50)

3 (60)
2 (40)

3 (60)
2 (40)

3 (75)
1 (25)

1 (17)
5 (83)

20
14.8 (12–17)
10
15.3 (13–17)
15
10.4 (9–11)

Assigned dose, mg/day
Mean age (range), years
Sex, n (%)
Male
Female
Race, n (%)
White
Black/African American
Other
DSM-IV-TR diagnosis, n (%)
Depressive disorder
Anxiety disorder
Depressive and anxiety disorder

5
10.8 (10–11)

10
9.4 (8–11)

20
10.2 (7–11)

5
15.0 (12–16)

15
15.2 (14–17)

AC4 (n = 6)
AC3 (n = 6)
AC2 (n = 6)
AC1 (n = 4)
CC3 (n = 5)
CC1 (n = 4)

CC2 (n = 5)

CC4 (n = 5)

Adolescent cohort
Child cohort

Table 1. Patient Demographics at Open-Label Extension Baseline

Downloaded by GEORGE WASHINGTON UNIV MED CTR from online.liebertpub.com at 10/23/17. For personal use only.

12.8 (7–17)

FINDLING ET AL.
Total (N = 41)

4

Although changes in vortioxetine dosing were allowed in the
OLE, all patients except two adolescents continued their dosage
assigned in the lead-in period for the duration of the OLE. One
patient’s dosage was increased from 5 to 10 mg/day due to lack of
efficacy. Another patient’s dosage was decreased from 20 to 10 mg/
day because of fatigue (which started during the lead-in period and
continued into the OLE).
Among the 41 patients who entered the OLE, 20 completed it.
The primary reasons for the 21 withdrawals were AEs (n = 4), lack
of efficacy (n = 3), noncompliance with treatment (n = 2), withdrawal of consent (n = 2), protocol violation (n = 1), lost to followup (n = 1), and administrative/other (needing concomitant ADHD
stimulant [applies to Germany; n = 3], moving to another state
[n = 1], miscalculating the visit window [n = 1], not returning to the
site for next study visit [n = 1], poor cooperation [n = 1], and disinterest in continuing the medication [n = 1]). No trends with regard
to age, sex, baseline diagnoses, comorbid ADHD, ADHD treatment, or time to withdrawal were observed for the patients who
withdrew.
Overall, the mean (–standard deviation) exposure to vortioxetine
was 133 (–61) days. Nearly half of the patients (n = 19; 46%) took
vortioxetine for between 183 and 196 days. The majority of patients
received all scheduled doses of vortioxetine based on patient reports and the count of returned tablets at each visit. The mean
overall compliance rate was 97% (range, 83%–100%).
Safety and tolerability
Spontaneous AEs. An overview of TEAEs during the extension period is provided in Table 2. Thirty-five patients (85%)
experienced a TEAE during the OLE, and AE rates were similar
among cohorts. There were 57 TEAEs among the adolescent cohorts and 32 among the child cohorts. Overall, the TEAE profile in
children and adolescents appeared similar to that of adults (Baldwin
et al. 2016). The most common TEAEs (incidence ‡5% in the
overall population) in the extension period were headache, nausea,
dysmenorrhea (females), vomiting, toothache, upper respiratory
tract infection, and increased weight. Most TEAEs (86%) were
mild or moderate in severity, and none of the severe TEAEs was
considered related to vortioxetine by the investigator. There was no
relationship between the intensity of TEAEs and age or dose.
Approximately half of the patients (n = 21; 51%) experienced
TEAEs that were considered related to vortioxetine; the most
Table 2. Summary of Treatment-Emergent
Adverse Events
Total (N = 41)
Any TEAE
Serious TEAE
TEAE leading to withdrawal
TEAEs with overall incidence ‡5%
Headache
Nausea
Dysmenorrheaa
Vomiting
Toothache
Upper respiratory tract infection
Weight increase

35 (85)
3 (7)
4 (10)
11
8
4
6
3
3
3

(27)
(20)
(19)
(15)
(7)
(7)
(7)

Values are number of patients (percentage).
a
Sex-specific event; data represent percentage of female patients.
TEAE, treatment-emergent adverse event.
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common of these (occurring in ‡5 patients overall) were headache
(n = 8) and nausea (n = 7). All treatment-related AEs were mild or
moderate in severity, and there was no relationship between the
incidence of these TEAEs and age or dose. Three patients (all
adolescents) experienced a serious AE (suicidal ideation [n = 1],
intentional overdose and nonfatal suicide attempt [n = 1], and appendicitis [n = 1]), all of which were considered unrelated to the
study drug. All patients recovered from these events. Four patients
(all adolescents) withdrew due to an AE (irritability [n = 1], headache [n = 1], nausea [n = 1], and nonfatal suicide attempt [n = 1]).
The patient who attempted suicide was found to have stopped
taking the study medication and was withdrawn from the study for
that reason; the suicide attempt was considered unrelated to vortioxetine by the investigator. There were no deaths in this study.
The mean changes in body mass index (BMI) from lead-in
baseline to the last day of dosing in the OLE ranged from -0.35 to
0.86 kg/m2 for adolescents and from 0.42 to 2.43 kg/m2 for children. The mean changes in weight for the same period ranged from
-0.91 to 2.33 kg for adolescents and from 0.83 to 5.06 kg for
children. Fourteen patients (five adolescents and nine children) had
potentially clinically significant (PCS) changes in weight (increase
or decrease of ‡7%), which were reported only during the extension
period; 12 patients had an increase and 2 had a decrease. The two
patients with PCS weight decrease were obese [BMI for age, ‡95th
percentile (Centers for Disease Control and Prevention 2015a)]
at baseline, and the reasons for weight loss were attributed to dieting
and concomitant treatment with ADHD medication.
Of the 12 patients with PCS weight increase, 3 children were
overweight [BMI range for age, 85th–94th percentile (Centers for
Disease Control and Prevention 2015a)], 1 child was obese, and 3
adolescents were obese. The main reasons for weight increase in
these patients were height increase, growth spurt, and dietary
changes; 1 event was considered possibly related to the study drug,
occurring in an 11-year-old girl who was obese at baseline (BMI,
31.8 kg/m2) and whose BMI increased by 5.7 kg/m2. In 4 of the 12
patients who had PCS weight increase (2 adolescents and 2 children), the increase was observed only on the last visit of the extension period.
There were no clinically relevant changes in mean clinical laboratory values, vital signs, or ECG parameter values, nor were there
any meaningful differences in these parameters between age groups
or dosage cohorts. The majority of mean clinical safety laboratory
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values were within reference ranges, and no PCS laboratory values
were reported.
Mean vital sign values outside the reference range were generally isolated, and postbaseline PCS vital sign values were reported
for 21 patients (13 adolescents and 8 children), including PCS low
standing pulse rate (n = 6), PCS high standing pulse rate (n = 9), PCS
low supine pulse rate (n = 12), PCS high supine pulse rate (n = 1),
PCS low standing systolic blood pressure (n = 3), PCS low supine
systolic blood pressure (n = 1), and PCS low supine diastolic blood
pressure (n = 1). For nine patients, at least one of the postbaseline
PCS vital sign values also had been PCS at the lead-in screening or
baseline visit. Among the patients with PCS vital signs, one adolescent (vortioxetine 10 mg/day) had a corresponding TEAE (orthostatic heart rate response increased), which was considered
unrelated to the study medication. On day 140 of the OLE, this
patient’s standing and supine pulse rates were 146 and 128 beats/
min, respectively, and both returned to normal by day 168 (118 and
94 beats/min, respectively).
The only postbaseline PCS ECG parameter reported in the entire
study (both periods) was PCS low heart rate that occurred in six
patients (five adolescents and one child), which was reported in the
lead-in period. Four patients had isolated postbaseline PCS low
heart rate. In two of them, the low heart rate also had been PCS at
the screening and baseline visit. None of the PCS ECG values was
reported as an AE.
Pediatric Adverse Events Rating Scale. Similar to spontaneously reported TEAEs, the majority of PAERS symptoms were
mild or moderate in intensity. The PAERS symptoms of extreme
intensity were single events reported for individual patients. Figure 1 shows the distribution of patients according to their highest
intensity of any PAERS item.
Columbia Suicide Severity Rating Scale. Among patients
who participated in the OLE, the lifetime assessment performed at
the lead-in screening showed that two adolescents had experienced a nonfatal suicide attempt beforehand and that another two
adolescents had previously demonstrated preparatory acts or behavior. Fifteen patients (37%), including children and adolescents, had a history of suicidal ideation before the lead-in period.
No suicidal ideation or suicidal behavior was reported at OLE
baseline. During the OLE, two adolescents had nonsuicidal self-

FIG. 1. Distribution of patients according to highest intensity of any PAERS symptom by visit (OC). Patients affected by ‡1 PAERS
symptom: baseline, n = 38; week 2 (end of lead-in treatment period), n = 37; and week 26 (end of OLE treatment period), n = 15. PAERS,
Pediatric Adverse Events Rating Scale; OC, observed cases; OLE, open-label extension.
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period were maintained throughout the OLE among children and
adolescents (Fig. 3). On day 2 of treatment in the lead-in period, the
mean CGI-I score was 3.8 (no change from treatment initiation)
for children and adolescents who continued into the OLE. At the
end of the extension period, the mean CGI-I score was 2.3 (much
improved) for children and 1.9 (much improved) for adolescents.
The mean CGI-I scores for the individual child and adolescent
dose cohorts ranged from 2.2 (much improved) to 3.0 points
(minimally improved) at the end of the lead-in period and from
1.8 (much improved) to 3.0 points (minimally improved) at the
end of the OLE.
Discussion

FIG. 2. Mean CGI-S score during the lead-in period (days 1–14)
and extension period (days 14–182) in children and adolescents
(OC). LOCF reported for day 182. CGI-S, Clinical Global
Impressions–Severity of Illness; LOCF, last observation carried
forward; OC, observed cases.
injurious behavior, one of whom also reported nonsuicidal selfinjurious behavior in the lead-in period. During the OLE, five
patients reported suicidal ideation only. Another patient reported
suicidal ideation as well as suicidal behavior (via the C-SSRS)
and experienced related serious AEs (intentional overdose and
suicide attempt). All patients who reported suicidal ideation or
suicidal behavior during the OLE had experienced suicidal ideation before any treatment with vortioxetine.
Effectiveness
In general, children and adolescents experienced improvement in
illness severity as measured by CGI-S (Fig. 2). The mean change in
CGI-S score from pretreatment lead-in baseline for individual cohorts ranged from -0.8 to -1.6 at the end of the lead-in period and
from -1.0 to -3.0 at the end of the extension period. At lead-in
baseline, the mean CGI-S scores for children and adolescents continuing into the OLE were 4.2 and 4.1, respectively. At the end of the
OLE, the mean CGI-S scores were 2.8 and 2.0, respectively. Similarly, CGI-I results showed overall improvement in illness; the
improvements in mean CGI-I scores evident during the lead-in

FIG. 3. Mean CGI-I score during the lead-in period (days 1–14)
and extension period (days 14–182) in children and adolescents
(OC). LOCF reported for day 182. *CGI-I is scored based on
change; therefore, no score can be reported for day 1. CGI-I,
Clinical Global Impressions–Improvement; LOCF, last observation carried forward; OC, observed cases.

This OLE study was conducted in a binational sample of pediatric patients and allowed for continuation of vortioxetine
treatment for up to 6 months, with a goal of determining whether
the therapeutic doses of vortioxetine approved for adults (5–
20 mg/day) are appropriate for future clinical studies of vortioxetine in pediatric patients. Most patients from the lead-in period
continued into the OLE, and the results provide further evidence
that vortioxetine 5–20 mg/day is generally safe and well tolerated
and is associated with continued effectiveness in children (aged
7–11 years) and adolescents (aged 12–17 years) with a depressive and/or anxiety disorder. The findings of this extension study
are consistent with those of the lead-in period, which concluded
that an uptitrated dosing strategy of vortioxetine 5–20 mg/day is
suitable for future clinical studies of vortioxetine in pediatric
patients (Findling et al. 2017).
Overall, the TEAE profile in children and adolescents appeared
similar to that for adults; headache and nausea also were the most
common TEAEs in studies with adult patients (Baldwin et al.
2016). Of the 13 headache events in the present OLE, most (n = 10)
lasted between 2 hours and 6 days. Of the nine nausea events in the
OLE, most (n = 6) lasted between 1 and 6 hours. As for the 14
patients with PCS weight change, the mean (–standard deviation)
BMI increased by 1.80 (–1.99) kg/m2 during the entire study. Of the
17 patients with concurrent ADHD, 7 were treated with stimulants
in both study periods. No safety issues related to concomitant
treatment with stimulants were identified. This is important given
that pediatric patients with ADHD often have a comorbid depressive or anxiety disorder, and there is a frequent use of stimulants in
these patients (Daviss 2008; Merikangas et al. 2010; Larson et al.
2011; Cuffe et al. 2015).
Based on the PAERS, the signs and symptoms reported during
the extension period and during the entire study (combined periods)
reflected symptoms of the patients’ illness and the TEAEs reported
spontaneously. Moreover, there was generally a decrease over time
in the incidence and intensity of the signs and symptoms collected
using the PAERS. At OLE conclusion, the majority of symptoms
were mild. C-SSRS findings showed that six patients experienced
suicidal ideation or behavior during the OLE, all of whom were
adolescents and had reported these symptoms at lead-in baseline.
None of these events was considered related to vortioxetine or
resulted in suicide completion, which is consistent with the currently understood relationship between antidepressants and suicidality risk (Birmaher and Brent 2005; Dubicka et al. 2006; Bridge
et al. 2007; Gibbons et al. 2012; Ho 2012).
Although assessment of effectiveness was not a main objective of
the OLE, CGI-S scores were found to improve during vortioxetine
treatment. Most of the improvements occurred in the lead-in period
and were maintained throughout the 6-month OLE. Similarly, CGI-I

VORTIOXETINE LONG-TERM PEDIATRIC SAFETY
results indicated substantial improvement in illness among children
as well as adolescents.
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Limitations
This was an open-label study in a relatively small sample of
pediatric patients. Because it was a long-term study in pediatric
patients, a withdrawal rate of *50% would not be unexpected
(Atkinson et al. 2014). Although self-reported adherence was very
high, this could not be definitively confirmed because patients were
not required to remain at the study site throughout the OLE. Due to
the small sample size and lack of placebo control, effectiveness
results are strictly exploratory and thus should be interpreted with
caution. Throughout the study (both periods), there were no restrictions with respect to concomitant psychotherapy; therefore, the
effect that concomitant psychotherapy may have had on the safety
and effectiveness outcomes is not known.
Conclusions
This OLE provides further evidence that vortioxetine, 5–20 mg/
day, is often well tolerated and is associated with effectiveness for
up to 6 months in children and adolescents with a depressive or
anxiety disorder. Results from the current study suggest that vortioxetine at dosages of 5–20 mg/day and the employed uptitration
scheme are appropriate for use in clinical trials that will more
definitively evaluate vortioxetine in pediatric patients.
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